Skip to main content

Hypertrophic Cardiomyopathy News

Related terms: Cardiomyopathy, hypertrophic, HCM

U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

PRINCETON, N.J.-- April 17, 2025 – (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information...

MEK Inhibition Beneficial for Children With Subset of Severe Hypertrophic Cardiomyopathy

MONDAY, Jan. 13, 2025 – For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces...

AI-Enabled Stethoscope Boosts Diagnosis of Pregnancy-Related Cardiomyopathy

TUESDAY, Sept. 10, 2024 – In pregnant and postpartum women, artificial intelligence (AI)-guided screening using a digital stethoscope improves the diagnosis of pregnancy-related cardiomyopathy,...

FDA Approves Camzyos (mavacamten) for the Treatment of Symptomatic NYHA Class II-III Obstructive Hypertrophic Cardiomyopathy

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules)...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

nifedipine